Research & Development in
Allschwil
29 companies in Research & Development based in Allschwil — name and year of registration from the commercial register. The list below shows them all.
All 29 companies in Allschwil
Pharmatrans Sanaq AG
Since 1982 · 11–20 empl.
The core activity of Pharmatrans SANAQ AG is the development, manufacture and distribution of excipients and active ingredients for the pharmaceutical industry. The company offers standardized and customer-specific solutions and supports its customers in the development and production of medicinal products.
Actelion Pharmaceuticals Ltd
Since 1997 · 21–50 empl.
Actelion Pharmaceuticals Ltd is a pharmaceutical company focused on the research, development, and marketing of medicines. The website presents Johnson & Johnson Innovative Medicine’s therapeutic areas, including oncology, immunology, neuroscience, and cardiopulmonary care.
ROLIC Technologies AG
Since 1998 · 11–20 empl.
ROLIC Technologies AG develops and sells ready-to-use formulations and functional films for displays, security documents, and other applications in the optical industry. The company also provides materials for thin-film encapsulation and barrier films.
Vortex Europe AG
Since 2012 · 1–10 empl.
Vortex Europe AG provides products, technologies and services for trenchless rehabilitation of water and wastewater infrastructure. Its portfolio includes coatings and materials, liner systems, sewer robotics, sensors and software, as well as trenchless installation services.
OncoGenomX AG
Since 2019 · 1–10 empl.
OncoGenomX AG provides PredictionStar, a therapy decision-support tool for breast cancer that analyzes tumor-specific genomic, biological, pathological and clinical data to inform treatment composition. The point-of-care platform applies patented algorithms and machine-learning–assisted drug–tumor matching, delivers analysis reports within the hospital IT environment without additional invasive procedures, and is designed for routine clinical use.
DeltaMem AG
Since 2016 · 11–20 empl.5.0(2)
The core activity of DeltaMem AG is the development and supply of membrane technologies and plants for the dehydration of organic solvents in the pharmaceutical, biotechnology, bioenergy and fine chemical industries. In particular, the company focuses on pervaporation and cross-flow filtration to clean and concentrate solvents. DeltaMem AG develops and supplies customized plants and solutions for industry, including membrane modules, process engineering and optimization.
InCephalo AG
Since 2021 · 1–10 empl.
The core activity of InCephalo Therapeutics is the development and research of local therapies for neurological diseases, particularly brain cancer. The company focuses on the development of biological drugs specifically designed for local application in the central nervous system (CNS) to minimize side effects and maximize efficacy. The proprietary Compartment Lock technology (C-Lock) enables the local retention of biological drugs in the CNS, prolonging their effect while minimizing systemic exposure.
Bright Peak Therapeutics AG
Since 2017 · 51–100 empl.5.0(1)
The core activity of Bright Peak Therapeutics is the development of cancer medications, particularly in the field of immuno-oncology, antibody-drug conjugates (ADCs) and biologics.
BioConcept AG
Since 1988 · 1–10 empl.3.4(7)
The core activity of BioConcept Ltd. is the manufacture and distribution of products and services in the field of biotechnology and life sciences, particularly in the areas of cell culture, molecular biology, immunology and microbiology. This includes the development and production of customer-specific cell culture media, enzymes, antibodies, cell lines, tissue samples and other biological products, as well as the provision of services such as pipette and cycle maintenance.
DMS Consulting GmbH
Since 2022 · 1–10 empl.
The core activity of VAKUMIN GmbH is the development, manufacture and marketing of high-quality cookware, in particular vacuum cooking pots, which enable energy savings and sustainable kitchen practices through their innovative technology.
Phialogics AG
Since 2022 · 1–10 empl.
INNOSIAMO AG
Since 2024 · 1–10 empl.
INNOSIAMO AG helps startups accelerate innovation in healthcare and create sustainable value through collaborations. The company focuses on supporting innovation projects with impact in the healthcare sector.
Crystallise! AG
Since 2017 · 1–10 empl.4.0(1)
The core activity of Crystallise! AG is the crystallization of liquids and the analysis of crystals using X-ray and electron diffraction (micro-ED). The company provides services in the fields of crystallization, structure elucidation and identification of molecules, particularly for the pharmaceutical, chemical and agro-industry. It supports customers in the crystallization of active pharmaceutical ingredients (APIs), co-crystals/salts, polymorphic forms, natural products and other small molecules.
Monix Health AG
Since 2025 · 1–10 empl.
Monix Health AG develops a real-time hormone monitoring platform for women that combines a non-invasive wearable biosensor patch with an AI-powered app. The technology continuously detects LH and progesterone, transmits data to devices and clinicians, and is intended to support clinical timing decisions such as during IVF while reducing repeated blood draws.
Nanolynx Biologics AG
Since 2025 · 1–10 empl.
Nanolynx Biologics AG develops conditionally active nanobody-drug conjugates (CA-NDCs) for hard-to-treat solid tumors. The company uses an AI-enabled discovery platform and focuses on tumor-selective biologics for oncology targets such as CD70, CD142 and Nectin-4.
Gubra GmbH
Since 2026 · 1–10 empl.
Gubra GmbH is a biotechnology company operating through Biotech, CRO services and Ventures. It develops peptide-based drug candidates and provides preclinical research and development services across areas such as obesity, liver, kidney, lung and metabolic diseases.
GlioCART GmbH
Since 2025 · 1–10 empl.
GlioCART GmbH develops a dual-action CAR-T therapy for glioblastoma. The company focuses on directly attacking tumor cells while also reprogramming the immunosuppressive tumor microenvironment.
Swiss Biome Institute GmbH
Since 2025 · 1–10 empl.
Swiss Biome Institute GmbH provides microbiome analysis to support clinical trials in functional foods, biotherapeutics and microbiota research. The institute performs advanced omics analyses (genomics, transcriptomics, proteomics, metabolomics), supports product efficacy validation and R&D project planning and implementation including computational analysis, and conducts epigenetic and mitochondrial research related to longevity using AI and in vivo studies.
Cancentus GmbH
Since 2026 · 1–10 empl.
Immuna Therapeutics AG
Since 2025 · 1–10 empl.
Immuna Therapeutics AG develops cell and gene therapies, with a focus on CAR-T and gene therapy platforms for blood cancers and other indications. The company supports hospitals and health systems with decentralized GMP manufacturing, regulatory support, and commercialization.
BIIE AI Initiative AG
Since 2025 · 1–10 empl.
BIIE AI Initiative AG is the AI initiative of the Botnar Institute of Immune Engineering (BIIE). The website mainly provides privacy policy information and a contact/newsletter form; it contains little detail about specific products or services.
SRS Schärer Research Services
Since 2002 · 1–10 empl.
Intelligence Research Services GmbH
Since 2003 · 1–10 empl.
Auxenion Research AG
Since 2017 · 1–10 empl.
noul GmbH
Since 2019 · 1–10 empl.
Treeline Biosciences GmbH
Since 2023 · 1–10 empl.
EqVita AG
Since 2024 · 1–10 empl.
Sironax Switzerland GmbH
Since 2025 · 1–10 empl.
Zhang Auberson Clinical Development Consulting
Since 2026 · 1–10 empl.
Research & Development in Allschwil
Research & Development in the region
Point size by number of companies per place.
Source: commercial register (Zefix) · as of October 10, 2026
Research & Development in other places
By canton